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Abstract. A fast, non-equilibrium enzyme-linked flow-injection immu- 
noassay (FIIA) system using an immobilized secondary-antibody 
reactor is described. The assay method is based on the competition 
between the enzyme-labeled antigen and analyte (unlabeled antigen) for 
a limited amount of soluble primary-antibody binding sites. This 
mixture is then introduced via flow-injection into the secondary- 
antibody reactor. The reactor bound enzyme activity, as measured by 
flowing an appropriate substrate solution through the reactor, is 
inversely proportional to the concentration of free analyte in the 
sample. By using non-equilibrium conditions, a single assay takes a total 
time of 15 min or less including regeneration of the reactor. To illustrate 
the application of this system, theophylline and insulin were chosen as 
model hapten and macromolecule analytes, respectively. Preliminary 
studies suggest that the new FIIA system is suitable for determining 
theophylline in serum with acceptable accuracy and precision. 
Key words: theophylline, insulin, competitive binding assays, flow 
injection analysis, ion-selective electrode. 
In recent years, newer enzyme-immunoassay (EIA) methods have essen- 
tially replaced classical radioimmunoassay (RIA) procedures for the 
detection of a wide variety of biomolecules (e.g., proteins, drugs, hormones, 
etc.) at trace levels [1--4]. Modern EIA methods can be grouped into two 
classes: homogeneous and heterogeneous. The more widely used heteroge- 
neous (or solid-phase) procedures are often based on the competition 
between the analyte and enzyme-labeled analyte for a limited number of 
primary(lst)-antibody binding sites (antibody toward analyte) immobilized 
on solid particles. After a lengthy equilibration period and subsequent sepa- 
ration and washing steps, the enzymatic activity bound to the solid phase is 
determined by adding the substrate(s) for the enzyme. Bound enzymatic 
activity is inversely related to concentration of analyte in the sample. At 
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present, solid-phase EIA methods based on this protocol are quite time 
consuming and involve many manual pipetting and washing steps which 
increase the potential for error, and hamper efforts to fully automate such 
methods. We now report on the use of a novel flow-injection arrangement 
in conjunction with an immobilized secondary(2nd)-antibody reactor which 
can be used to simplify and speed-up heterogeneous EIA procedures. 
The development of EIA arrangements involving flow-through 
immunosorbents and a variety of downstream detectors has been reported 
previously [5, 6]. In most cases, the 1st antibody has been immobilized on 
solid particles (e.g., silica) and packed into a small flow-through reactor. 
Preparation of such lst-antibody reactors requires careful control of the 
coupling conditions and amount of lst-antibody actually linked to the 
packing material. This is because the lst-antibody is typically the limiting 
reagent in these assays and the immobilized binding site concentration 
dictates the ultimate detection limits of the method. Random orientation of 
the immobilized 1st-antibody molecules can also cause heterogeneity in 
binding affinities (including lower affinity) toward analyte and enzyme- 
labeled analyte. In addition, for repetitive use, such columns must be 
continually regenerated by dissociating the bound analyte and enzyme- 
labeled analyte conjugates after each assay. These regeneration steps 
(usually pH _ 4.0) may result in loss of specific analyte binding ability, and 
with time, this can seriously affect the observed dose-response behavior of 
the system (binding less enzyme-labeled analyte). Such antibody denatur- 
ation has been observed previously with immunosensors based on immo- 
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Fig. 1. Schematic diagram illustrating the principles of the solid-phase enzyme-linked FIIA 
system 
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In this report, we describe a new flow-injection immunoassay system 
(FIIA) which makes use of immobilized 2nd-antibodies as a means of sepa- 
rating bound and free enzyme-labeled analyte in a flowing sample solution. 
Fig. 1 illustrates the principles of the proposed system. The sample 
containing the analyte is first equilibrated with given amounts of enzyme- 
analyte conjugate and 1st-antibody. Since the 1st-antibody is added as a 
soluble reagent, its site concentration can be well controlled, and its natural 
affinity and homogeneity is preserved. After a brief non-equilibrium incu- 
bation period, the reaction mixture is injected through the immunosorbent 
reactor containing excess 2nd-antibody (antibody which selectively binds 
the 1st-antibody). A fixed fraction of the total 1st-antibodies binds to the 
column (non-equilibrium amounts) with associated analyte or enzyme- 
labeled analyte. All unbound species are washed away by the carrier stream 
buffer. Enzyme activity bound to the reactor can be detected by diverting a 
flowing solution of substrate through the reactor, and monitoring the 
product downstream with an appropriate flow-through electrochemical or 
photometric detector. After detecting bound activity, the reactor is regen- 
erated by diverting a low pH buffer through the column for brief period. As 
shown in Fig. 2, the flow of various solutions through the system is 
controlled by several rotary injection valves. 
To demonstrate the FIIA concept described above, we have chosen 
theophylline and insulin as model analytes. In the case of theophylline, 
adenosine deaminase (ADA) is used as the labeling enzyme, and its activity 
is detected downstream with an ammonium ion-selective" electrode. For 
insulin, horseradish peroxidase (HRP) is employed as the label with photo- 
metric detection of bound enzyme activity. Sheep anti-theophylline and 
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Fig. 2. Flow and valve arrangement used in 2nd-antibody reactor based FIIA system. Flow 
rate of buffer stream controls contact time between 2nd-antibody reactor and lst-antibody 
reaction mixture injected via rotary valve 2. Buffer flow rate was 0.7 ml/min for insulin 
system and 0.2 ml/min for most theophylline measurements 
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contain immobilized anti-sheep whole serum and anti-guinea pig whole 
serum, respectively. Using these reagents, reactors, and the flow configu- 
ration illustrated in Fig. 2, it will be shown that very rapid (e.g., 10--15 rain) 
and selective heterogeneous enzyme-linked methods for detection of small 




The flow system used for the FIIA measurements is shown in Fig. 2. A Rainin Rabbit peri- 
staltic pump was used to deliver the sample and buffers through the system. Potentiometric 
measurement of the ammonium ions produced from the adenosine deaminase (ADA) cata- 
lyzed reaction was made using a tubular flow-through ammonium ion-selective electrode 
similar in design to that described previously [8, 9]. The potential readings were taken on an 
Altex Selection 2000 p H / m V  meter and recorded on a Linear Model 1201 strip-chart 
recorder. The flow-through spectrophotometer used to detect peroxidase activity was a micro 
flow-through cell fitted in the center of the light path of a Sequoia Turner Model 340 Spec- 
trophotometer and connected to a Linear Model 1201 strip-chart recorder. 
Samples were delivered to the electrode or spectrophotometer by the flow injection 
system, using a 4-way flow injection valve from Rheodyne, Incorporated. The reactor was 
also a Rheodyne 4-way Rotary Teflon valve, with the sample loop removed and replaced by 
silicone rubber filled with solid-phase particles. Connections were made by using short 
sections of tight-fitting silicone tubing to sleeve the tubes to be joined. 
A Perkin-Elmer Lambda Array 3840 photodiode array UV/VIS spectrophotometer 
operated by a Model 7300 Professional computer was used to record the UV/VIS spectra of 
enzymes, theophylline, insulin, and conjugates. 
Reagents 
The following materials were purchased from Sigma Chemicals Co. (St. Louis, MO): aden- 
osine deaminase (ADA) (E.C. 3.5.4.4) type VI, horseradish peroxidase (HRP) (E.C. 1.11.1.7) 
type IV, anti-sheep whole serum (fractionated-rabbit; 42.5 mg protein/ml), anti-guinea pig 
whole serum (fractionated-rabbit; 30rag protein/ml), N,N'-dicyclohexylcarbodiimide 
(DCC), N-hydroxysuccinimide (NHS), theophylline, bovine insulin, bovine serum albumin 
(BSA) (fraction V) and Sephadex G-200. Sheep anti-theophylline antiserum was obtained 
from Research Plus Inc. (Bayonne, N J). Anti-insulin (guinea pig) was a product of Miles 
Lab., Inc. (Naperville, IL). Therapeutic Drug Control Sera were obtained from Fisher Scien- 
tific Co. (Detroit, MI), CNBr-activated Sepharose 4B from Pharmacia Fine Chemicals 
(Uppsala; Sweden), Nylon 6/6 balls (3.2 mm) from Precision Plastic Ball Co. (Chicago, IL) 
and Carbonyldiimidazole(CDI)-activated glycerol-coated controlled pore glass (CPG) beads 
(250 A pore, 120/200 mesh) from Pierce Chemicals Co. (Rockford, IL) were examined as 
solid-phase supports for preparation of the 2nd-antibody reactor. 2,2'-Azino-di-[3-ethyl- 
benzothiazoline-sulphonate(6)] (ABTS) was obtained from Boehringer Mannheim Co. (Indi- 
anapolis, IN). All other chemicals and solvents used were of analytical or reagent grade. 
Deionized water was used to prepare all solutions and buffers. 
Buffers 
The theophylline assay buffer was 0.05 M tris(hydroxyamino)methane-hydrochloric acid 
(Tris-HC1), pH 7.5. The assay buffer for insulin was 0.05 MNaH2PO4/Na2HPO4, pH 7.0. The 
Enzyme-Linked Flow-Injection Immunoassay 211 
dilution buffers for theophylline and insulin conjugates, antibodies, and standards were 
prepared using the assay buffers containing 0.1 M NaC1, 0.10% (w/u) gelatin, 2.0% (w/u) 
bovine serum albumin, and 0.01% (w/v) sodium azide. The reactor regeneration buffer was 
0.2 M glycine-HC1, pH 2.2. Bound ADA activity was measured by flowing a 0.25 mM aden- 
osine solution, prepared in the theophylline assay buffer, through the reactor. HRP activity 
measurements were made using a solution containing 2.0 mM ABTS and 6.0 mM H202 
prepared in 0.1 M sodium acetate/0.05 M NaH2PO4, pH 4.0. 
Preparation of 2nd-Antibody-CPG Beads 
The immobilization procedure was performed by suspending 400 mg of 
CDI-activated glycerol-coated CPG beads in a mixture of 1200 #1 of 0.1 M 
sodium borate buffer, pH 8.5, and 300 ill of rabbit anti-sheep whole serum 
antiserum (antibody fraction) or sheep anti-guinea pig whole serum 
antiserum (antibody fraction) [10, 11]. This suspension was first degassed 
with ultrasonic vibration for 20 rain, and then shaken for 2 days at 4 ~ C. The 
remaining active hydroxyl groups on the beads were deactivated by 
treatment with 2 M ethanolamine. The suspension was then centrifuged and 
the beads were washed repeatedly with assay buffer. Based on absorption 
measurements at 280 nm, approximately 17 mg of total protein from each 
fractionated anti-sera was coupled to 1 g of CPG beads. 
Preparation of 2nd-Antibody Reactor 
The 2nd-antibody-CPG beads (approximately 120 mg, dry weight) were 
slurried in an assay buffer and packed into a silicone tubing (2.54 mm 
i.d. x 2.7 cm). A thin plug of glass wool was placed at each end of the 
reactor to prevent leakage and movement of the CPG beads by the carrier 
stream. The 2nd-antibody reactor was stored at 4~ between experiments 
and filled with assay buffer containing 0.01% (w/v) sodium azide. 
Preparation of Theophylline-ADA Conjugates 
Theophylline-8-butyric acid lactam was synthesized by the modified 
method of Cook [12]. To prepare the theophylline-ADA conjugates, four 
different amounts of the theophylline-8-butyric acid lactam were added to 
four solutions, containing 72 units of enzyme (previously dialyzed versus 
sodium bicarbonate buffer, 0.1 M, pH 8.5). After mixing overnight, the 
reaction mixtures containing the enzyme conjugates were dialyzed five 
times at 4~ against 0.05 M Tris-HC1, pH 7.5. Each conjugate was charac- 
terized by the degree of conjugation (moles of theophylline/mole of 
enzyme) and by its residual enzymatic activity. The degree of conjugation 
was estimated from calculations involving absorbance measurements at two 
absorption maxima of the conjugate (230 nm and 283 nm). 
Preparation of lnsulin-HRP Conjugate 
The alpha and epsilon amine functional groups of insulin were modified by 
treatment with succinic anhydride to form carboxylic acid derivatives [13]. 
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The resulting derivatized insulin was then reacted with NHS to form N- 
hydroxysuccinimide esters [14]. The enzyme conjugation reaction was 
performed by adding the required amount of NHS-activated insulin to 4 mg 
of HRP in 800 #1 of 0.1 M sodium bicarbonate buffer, pH 8.5, at 4~ with 
stirring overnight. The reaction mixture was then dialyzed against 0.05 M 
phosphate buffer, pH 7.0, and further purified (to remove unreacted 
insulin) by gel chromatography (Sephadex G-200, 40 x 1 cm) in the same 
buffer. Each 1.5 ml of effluent was assayed for HRP and protein content by 
monitoring absorbances at 403 nm and 280 nm. The first protein peak 
(highest MW) was the desired insulin-HRP conjugate. This conjugate 
fraction was diluted (1 :4)  and then used in the subsequent FIIA proce- 
dures without further purification. 
Theophylline and Insulin lst-Antibody Dilution Curves 
In order to determine the binding capacity of the 1st-antibodies for the 
conjugates, varying concentrations of 1st-antibody were incubated with a 
fixed amount (50#1) of the appropriately diluted conjugate. The final 
volume of each vial was brought to 100/.tl with assay buffer containing 
BSA. The vials were incubated for 7 min, and this mixture was introduced 
into the 2nd-antibody reactor (anti-sheep serum or anti-guinea pig serum). 
The bound enzymatic activity was measured by flowing the appropriate 
substrate solution through the reactor. 
Preparation of Standard and Sample Solutions 
Working theophylline standards were prepared by diluting a stock solution 
of theophylline (10-3M in H20 ) with Tris-HC1 buffer containing BSA and 
EDTA. These solutions were freshly prepared for each standard curve. 
Fisher Diagnostics Therapeutic Drug Controls (TDC) were used as control 
sera. The high and low levels of TDC were diluted 1 : 400 with Tris-BSA 
buffer containing 1 mM EDTA before assaying for theophylline. 
The insulin stock solution was 10 mg of bovine insulin (Sigma, lot 57F- 
0242, 25.6 I.U./mg) dissolved in I ml of 0.03 N HC1 which was then diluted 
to 100 ml with phosphate-BSA buffer. This stock solution was stored 
frozen. The working standards were diluted from this stock solution daily 
with the phosphate-BSA buffer. 
Theophylline and Insulin Dose-Response Curves 
The typical FIIA procedure used for both analytes was as follows : A known 
amount of enzyme-labeled analyte (35/.tl) and a given amount of standard 
free analyte (35/.tl) were mixed with 35/.tl of 1st-antibody and 35 ~ul assay 
buffer. This mixture was shaken for 7 min. The mixture was then loaded 
into the sample loop (valve 2 in Fig. 2) and injected into the 2nd-anti- 
body-CPG reactor. The actual exposure time for this mixture with the 2nd- 
antibody column was very short (approximately 5 s); after which the carrier 
buffer stream washed off the unbound species for 4 min. When the valve of 
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the reactor injector was opened, substrate solution passed through the 
reactor. The products of the enzymatic reactions were measured by down- 
stream with an ammonium ion-selective electrode (theophyll]ne) or spectro- 
photometer (insulin). Results were recorded on a strip-chart recorder. The 
system was regenerated by washing with 0.2 M glycine-HC1 buffer, pH 2.2, 
for 2 rain to dissociate the complex between the 1st antibody and immo- 
bilized 2nd-antibody, after which the system was ready for another sample. 
Dose-response curves were prepared by plotting detected ammonium 
ion concentration versus logarithm of the theophylline concentration in the 
standards. The insulin dose-response curve was prepared by plotting 
absorbance at 405 nm versus logarithm of the bovine insulin concentration 
in the standards. 
Results and Discussion 
Initially, several solid-phase support materials were evaluated for prepa- 
ration of the 2nd-antibody reactor. CNBr-activated Sepharose 4B is a 
common support used in affinity chromatography; however, because of 
poor mechanical strength, Sepharose 4B could not be employed here due to 
the relatively high flow rates used in the FIIA system [15]. Smaller and more 
durable Nylon balls and CPG beads were also examined. Unfortunately, 
severe non-specific protein adsorption on the normal CPG beads [16], and 
the lower surface area of the Nylon balls, limited their use in the immu- 
noassay system. Ultimately, 1,1-carbonyldiimmidazole(CDI)-activated, 
glycerol-coated CPG beads were chosen as the solid-phase material to 
prepare the 2nd-antibody reactor. This material consists of normal CPG 
beads first treated with a hydrophilic, glycophase layer which removes the 
ionic and denaturing properties of the uncoated glass. The glycophase layer 
is then activated with CD! to produce a support which has high capacity for 
covalently binding proteins, low non-specific protein adsorption, and 
excellent long-term stability [17]. Other advantages include its high 
mechanical strength (enabling high flow rates) and greater surface area 
(compared to non-porous supports). Once reacted with the appropriate 
2nd-antibody reagent, the glycerol-coated CPG beads could be stored at 
4~ in phosphate buffer, pH 7.0, with 0.01% (w/v) NaN3 for several months 
with little or no change in 1st-antibody binding ability. 
The analytical utility of any EIA method is controlled, to a large extent, 
by the quality of the enzyme-analyte conjugates used as competitive binding 
reagents. Therefore, we expended considerable effort, particularly in the 
case of the theophylline assay, to prepare conjugates with substantial 
residual catalytic activity. For example, Table 1 summarizes the character- 
istics of four theophylline-ADA conjugates synthesized with varying initial 
ratios of theophylline-8-butyric acid lactam and ADA. As shown, as the 
number of theophylline molecules attached to the ADA increases, the 
activity of the conjugate decreases. For most of the studies reported here, a 
I : 200 dilution of conj-1 was used. In the case of the insulin method, final 
size exclusion purification of the insulin-HRP conjugate yielded a very 
broad band of protein. The protein fraction with the highest molecular 
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Table 1. Characteristics of theophylline-adenosine deaminase conjugates 
Conjugate Initial ratio oP Degree of % Residual b, c 
theophylline/enzyme conjugation activity 
Conj-1 25 1.4 94.2 
Conj-2 50 2.0 86.5 
Conj-3 125 3.2 78.8 
Conj-4 250 3.9 77.9 
a Refers to molar ratios of theophylline lactam to adenosine deaminase in 
the conjugation reaction mixture 
b Measured by optical absorbance change at 260 nm [18], not by electrode 
methods 
c Measured relative to the same concentration of ADA used for conju- 
gation reaction but without addition of theophylline lactam (i.e. blank) 
weight, indicating high degree of insulin attachment to HRP, was used in 
the assays (diluted 1:4) .  
A typical timing sequence and signal output of the proposed FIIA assay 
scheme is depicted in Fig. 3 (for the theophylline assay). After equilibrating 
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Fig. 3. Typical strip-chart recording showing the valve cycling and resulting output for the 
theophylline enzyme-linked FIIA system. Levels of theophylline refer to concentrations 
within injected reaction mixture 
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controlled period, the 100yl of the reaction mixture is introduced into the 
sample loop (valve 2 in Fig. 2) and injected through the 2nd-antibody 
reactor with assay buffer as the carrier stream solution. A third rotary valve 
controls whether the assay buffer or regeneration buffer (glycine) passes 
through the reactor. Substrate solution is diverted through the reactor by 
turning the valve which houses the reactor. The resulting peak heights are 
directly (insulin) or logarithmically (theophylline) proportional to the en- 
zymatic activity bound to the reactor's solid-phase. Although manually 
operated for these experiments, improvements in assay precision and 
sample throughput could be achieved if valve operations were computer 
controlled. The shoulders on the rising portion of the substrate-response 
curves shown in Fig. 3 are due to trace levels of ammonium chloride added 
to the Tris-HC1 wash buffer in order to speed the response time of the 
ammonium ion-selective electrode toward low levels of NH2- produced 
from the ADA reaction. 
Dose-response curves for theophylline were prepared by plotting the 
percent of bound enzymatic activity (relative to zero-dose analyte, B/Bo) vs. 
logarithm of analyte. For insulin, direct measurement of product absorption 
(405 nm) was used as an indicator of bound enzyme activity. Figs. 4 and 5 
illustrate typical curves obtained. The working range for theophylline was 
(0.025 #M--0.25 #M) and 1- -250#g/ml  for insulin (concentrations in 
reaction mixture injected into system). For the most part, detection limits in 
these FIIAs are controlled by the amount of soluble lst-antibody required 













I i I I I I I I 
- '  - - 8  - - 7  - - 6  - - ,5  
Log [theophylline], M 
Fig. 4. Representative dose-response curve for theophylline FIIA system. Ranges shown are 
for duplicate measurements of each standard. Levels of theophylline refer to concentrations 
within injected reaction mixture 
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Fig. 5. Typical dose-response curve for detection of insulin using immobilized 2nd-antibody- 
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Fig. 6. Effect of carrier buffer ([])  and substrate (O) flow rates on zero-dose peak signals 
observed for theophylline FIIA system 
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signal (for zero-dose analyte) upon flowing substrate through the reactor. 
This zero-dose signal is, in turn, related to the kinetics of the enzymatic 
reaction in the reactor and the binding of the 1st-antibody-enzyme 
conjugate complex to the immobilized 2nd-antibody. As shown in Fig. 6, 
for a given amount of the antibody and conjugate (theophylline system), the 
zero-dose signal decreases as the flow rate of either the substrate stream or 
sample injection stream (buffer) is increased. This is due to the non-equi- 
librium nature of the reaction processes within the reactor. At higher flow 
rates of sample and substrates (desired to achieve greater sample 
throughput), to increase the zero-dose signal, higher concentrations of 1st- 
antibody and enzyme-ligand conjugate must be used. Increasing these 
reagents tends to diminish the detection capabilities of the system. 
Improved detection limits concomitant with the desired faster flow rates 
can only be achieved if a more sensitive detection method is used to detect 
bound enzyme activity (e.g., fluorescence). 
Aside from optimizing the flow-rates to obtain a proper balance in 
terms of detection limits and sample throughput, the composition of the 
flowing solutions, particularly the substrate, is also important. For example, 
in the case of detecting the activity of the bound insulin-HRP conjugate, the 
concentrations of the flowing substrates (HzO 2 and ABTS) and the pH of 
this solution must be optimized to generate the maximum absorption signal 
(at 405 nm) from the bound conjugate. Moreover, the substrate concentra- 
tions must remain stable during the course of a given calibration. For this 
reason, the HRP substrate solution reservoir was kept at 0~  in the dark 
while the FIIA system was operating. The length of pump tubing between 
this solution and the reactor was made sufficiently long so that ambient 
temperature equilibration could take place before the solution passed 
through the reactor. While 6 mM HzO 2 and 2 mM ABTS proved optimal in 
terms of substrate concentrations, the pH optimum for the HRP reaction 
(with ABTS as substrate) is only pH 4.0 [19]. Initially, we assumed that such 
a low pH would completely dissociate the bound conjugate and, with time, 
help degrade the binding ability of the 2nd-antibody reactor. However, we 
ultimately found that these concerns were not realized due to the relatively 
short time (2--3 min) that the substrate actually flows through the reactor. 
The method and speed of regenerating the 2nd-antibody reactor was 
also studied. Whereas the pH 4.0 buffer used to prepare the HRP substrate 
solution did not rapidly dissociate the bound enzyme conjugates and/or  
1st-antibodies, further studies suggested that a 0.2 M glycine-HC1 buffer, 
pH 2.2, was quite efficient for such purposes. The kinetics of this immuno- 
desorption step is illustrated in Fig. 7 for the dissociation of the 
theophylline-ADA conjugate-lst-antibody complex. As can be seen, the 
signal generated from the adenosine substrate solution goes to zero after 
only 90 s of washing the reactor with the low pH buffer. Such treatment, 
repeated for every sample or standard, is not detrimental to the perfor- 
mance of the FIIA system. Indeed, 2nd-antibody reactors were run for over 
1 month without any significant decrease in the amount of enzyme-conju- 
gates bound to the solid-phase at zero-dose of analyte. Such results do not 
imply that the absolute binding ability of the 2nd-antibodies is maintained 
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Fig. 7. Effect of  contact  time between 
glycine-HC1 buffer  and 2nd-ant ibody 
reactor  on dissociat ing bound  
theophy l l ine -ADA conjugate 
after repeated treatment with pH 2.2 buffer. However, since the amount of 
2nd-antibody sites is in great excess to the amount of limiting 1st-antibody 
binding sites used in the assays, substantial loss in binding ability can be 
tolerated without observing a change in the magnitude of the analytical 
Table 2. Cross-reactivit ies of  theophyl l ine  F I I A  system 
C o m p o u n d  
% Cross-reactivity" 
F I I A  RIA b,c 
Theophyl l ine  100 100 
Caffeine 5.0 4.2 
Theobromine  0.3 0.09 
Xanthine  < 0.01 < 0.01 
Hypoxan th ine  < 0,01 < 0.01 
Uric acid < 0.01 < 0.01 
a Determined by dividing the concentrat ion of  theophyl l ine  
at 50 % of  the response,  by the concentrat ion of  analog that 
yields 50 % of  the max imum response 
b From ref. [11] 
c From ref. [19] 
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Fig. 8. Dose-response curves for xanthine analogs in theophylline FIIA system; (r~) 
theophylline, (/x) caffeine, (9 theobromine, (V) xanthine, (o) hypoxanthine, ( | )  uric acid 
signals. We believe this is the primary advantage of using immobilized 2nd- 
antibodies to perform the separation step in flow-through EIA methods. 
To demonstrate the analytical application of the proposed FIIA 
approach, more detailed studies were performed with the theophylline 
system. Fig. 8 illustrates the dose-response of this method toward several 
xanthine analogs. The percent cross-reactivity for each is tabulated in 
Table 2. The observed selectivity pattern is dependent on the association 
constants of the lst-anti-theophylline antibody towards the analogs relative 
to theophylline. The selectivity of this FIIA system agrees well with what 
has been observed previously using polyclonal anti-theophylline antibodies 
in an RIA theophylline method [20], and appears suitable for direct determi- 
nations of theophylline in serum. Indeed, Table 3 compares the results 
obtained using the FIIA-EIA system to values found by several commercial 
theophylline methods on two control sera. Recovery studies were also 
performed in which additional theophylline was spiked into the "low" 
serum control. As shown in Table 4, the amounts added could be recovered 
with good accuracy. 
In summary, a new heterogeneous enzyme-linked FIIA system has been 
described. The unique feature of this system is the use of an immobilized 
2nd-antibody reactor column to separate 1st-antibody bound enzyme- 
analyte conjugates. By careful control of the initial reagent equilibrium 
times, the non-equilibrium binding and enzymatic reactions which occur in 
the reactor can be utilized to achieve relatively rapid total assay times 
(compared to other heterogeneous systems). Via the use of more sensitive 
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Table 3. Comparison of  results for determination of  theophylline in 
low and high serum controls a 
Method Low (#g/ml) b High (#g /m0  b 
Abbott  TDX 4.6 + 1.5 28.6 ___ 5.6 
Ames TDA Manual  4.0 + 0.8 29.0 + 4.3 
Dade STRATUS 4.7 _+ 1.6 30.1 + 6.1 
DuPont  ACA 4.0 + 1.5 26.3 +_ 5.9 
HPLC 4.7 + 1.6 28.9 + 4.3 
IL M O N A C H  4.4_+ 1.0 29.0 +_ 4.3 
Pharmacia Diag. EIA 4.8 + 1.3 32.5 _+ 6.5 
Roche COBAS 4.4_+ 1.6 26.6 _+ 6.8 
Syva EMIT 4.4 + 1.6 26.6 + 6.7 
Present F I IA  System 4.8 + 0.4 c 32.2 _+ 2.2 c 
a EIA values from Fisher Therapeutic Drug Control Sera data sheet 
b + 2 standard deviation 
c Average of  four determinations + 2 standard deviation 
Table 4. Recovery of  standard theophylline additions to a drug 
control serum 
Added (#g/ml) Found (#g/ml) a % Recovery 
0 4.8 --  
10.0 14.6 98.6 
20.0 24.2 97.5 
a Average of  three determinations 
detection methods and fully automated reagent dispensing and valve 
controls, we believe that the proposed FIIA method could become an 
attractive approach for performing heterogeneous EIAs on a routine basis. 
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